STING
Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS
Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.
STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.
All Product Categories
-
STING Inhibitors
(50)
View all products
-
STING Agonists
(104)
View all products
-
STING Antagonists
(7)
View all products
-
STING Activators
(51)
View all products
-
STING Modulators
(5)
View all products
-
STING Degraders
(12)
View all products
-
STING Controls
(3)
View all products
-
STING Ligands
(3)
View all products
-
STING Related Products (251)
Related Products (251)
-
Antibodies (13)
-
STING agonist-13
0 ImagesCat. No.: HY-143321CAS No.: 2816929-48-1STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition.
-
STING antagonist-3
0 ImagesCat. No.: HY-185379CAS No.: 3106554-00-8STING antagonist-3 is a potent STING antagonist with an IC50 of 2.3 nM against human wild-type STING. STING antagonist-3 inhibits human wild-type STING and the gain-of-function STING mutants N154S and V155M. STING antagonist-3 suppresses IFN‑α2a production in stimulated human whole blood. STING antagonist-3 inhibits IP-10 production in activated human dermal microvascular endothelial cells (HMVEC-d). STING antagonist-3 can be used for the research of autoimmune diseases, autoinflammatory diseases, interferonopathies, and fibrotic disorders.
-
diABZI-a1
0 ImagesCat. No.: HY-175168CAS No.: 2138299-43-9diABZI-a1 is a orthosteric STING agonist with EC50 of 117 nM for IFNβ in human PBMCs. diABZI-a1 can be used for monogenic autoinflammatory disease like SAVI disease research.
-
VB-85247
0 ImagesCat. No.: HY-173404VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research.
-
STING agonist-44
0 ImagesCat. No.: HY-176257CAS No.: 3078213-34-7STING agonist-44 (Compound 4) is a potent and selective STING agonist with an EC50 value of 5.68 for IRF induction in THP1 cells and 2.212 μM in RAW cells. STING agonist-44 activates the STING pathway, inducing the production of type I interferons and pro-inflammatory cytokines (e.g., CXCL10, TNFα). STING agonist-44 is promising for research of cancers.
-
STING modulator-5
0 ImagesCat. No.: HY-148643CAS No.: 2305940-22-9STING modulator-5 (compound 38) is a STING modulator with a pIC50 value of 9.5. STING modulator-5 antagonizes peripheral blood mononuclear cells (PBMC) with a pIC50 value of 8.1. STING modulator-5 is a antagonist of THP-1 cells, it can be used for immunological disease research.
-
PPARα agonist 4
0 ImagesCat. No.: HY-159146PPARα agonist 4 (compound BH400) is a PPARα agonist (EC50= 1.2 μM). PPARα agonist 4 also inhibits STING (IC50: 8.1 μM). PPARα agonist 4 reduces the CoCl2-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS.
-
UM-242
0 ImagesCat. No.: HY-178047UM-242 is a STING inhibitor, with an EC50 of 1.70 μM in THP1-Dual cells expressing wild-type STING. UM-242 blocks STING oligomerization and inhibits diABZI-induced phosphorylation of TBK1 and IRF3, thereby suppressing the transcription of IFNβ and IL6 and reducing IFNβ secretion. UM-242 can be used for the study of STING-dependent inflammatory and neurological diseases.
-
STING-IN-17
0 ImagesCat. No.: HY-178951CAS No.: 3069635-58-8STING-IN-17 (compound 10a) is an orally active STING (human STING IC50 = 29 nM, mouse STING IC50 = 15 nM) inhibitor. STING-IN-17 can inhibit the phosphorylation of STING, TBK1 and IRF3. STING-IN-17 dose dependently inhibits the mRNA expression of IP10, IFNB1 and ISG56. STING-IN-17 can reduce ROS and inhibit the expression of cleaved-PARP/caspase-3. STING-IN-17 can improve kidney function. STING-IN-17 can be used for research on inflammatory conditions such as acute kidney injury.
-
Cytisine-platinum(IV) prodrug-1
0 ImagesCat. No.: HY-182360Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural compound Cytisine (HY-N0175) with antiproliferative activity against tumor cells. Cytisine-Platinum(IV) Prodrug-1 promotes calcium transfer across the IP3R1-GRP75-VDAC1 axis to drive mitochondrial calcium overload. Cytisine-Platinum(IV) Prodrug-1 initiates unfolded protein response via PERK, eIF2α, ATF4, and CHOP to modulate Bcl-2 and Bax, triggering apoptosis. Cytisine-Platinum(IV) Prodrug-1 induces mitochondrial dysfunction, ROS production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest. Cytisine-Platinum(IV) Prodrug-1 activates the cGAS-STING pathway, reduces PD-L1 expression, drives immunogenic cell death. Cytisine-Platinum(IV) Prodrug-1 exhibits high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding, and inhibits tumor growth in mouse models with reduced systemic toxicity. Cytisine-Platinum(IV) Prodrug-1 can be used for the research of lung cancer.
-
m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag
0 ImagesCat. No.: HY-158348CAS No.: 2553413-13-9m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag is a drug-linker conjugate for ADC.
-
DDO-88109
0 ImagesCat. No.: HY-184502CAS No.: 3034295-80-9DDO-88109 is a STING inhibitor with a Kd value of 317 nM for hSTING and 0.625 μM for mSTING. DDO-88109 competitively occupies the CDN-binding pocket of STING, thereby maintaining STING in an inactive state. It inhibits cGAS-STING signaling—including STING translocation from the endoplasmic reticulum to the Golgi apparatus, STING oligomerization, and the phosphorylation of IRF3, p65, TBK1, and STING—and attenuates the production of inflammatory cytokines and tissue inflammation in mouse models of TREX1-deficiency-driven autoinflammation and cisplatin (HY-17394)-induced acute kidney injury. DDO-88109 is suitable for research on inflammatory diseases, autoimmune disorders, and acute kidney injury driven by the cGAS-STING pathway.
-
Enpp-1-IN-27
0 ImagesCat. No.: HY-175478CAS No.: 3105103-33-8Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC50 of 14.68 nM, exhibiting approximately 410-fold selectivity against ENPP2 and 10-fold selectivity against ENPP3. Enpp-1-IN-27 stabilizes cGAMP levels and activates the STING pathway, promoting cytokine release and enhancing innate immune responses. Enpp-1-IN-27 induces ISRE activation and amplified cGAMP-mediated immune responses and shows the desired antitumor efficacy in the 4T1 and CT26 syngeneic mouse models. Enpp-1-IN-27 can used for the studies of breast cancer and colon cancer.
-
UM-203
0 ImagesCat. No.: HY-180120UM-203 is a reversible covalent STING antagonist. UM-203 is effective against both mouse and human STING, and in particular, it inhibits the most common human STING R232 variant. UM-203 can inhibit STING oligomerization and reduce phosphorylation of downstream TBK1 and IRF3, thereby blocking the IRF3 and NF-κB-mediated signaling pathways and inhibiting IFNβ and IL-6 secretion. UM-203 can be used for the research of inflammation and immunology, such as systemic lupus erythematosus.
-
STING agonist-18 diTFA
0 ImagesCat. No.: HY-150074ACAS No.: 2138299-69-9STING agonist-18 (compound 1a) diTFA is a STING agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate.
